neoadjuvant imatinib

Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib

This study compares radiographic versus pathology-integrated response metrics to identify optimal surgical timing after neoadjuvant imatinib treatment in KIT exon 11-mutant gastrointestinal stromal tumors (GIST). Pathology measures indicate